Premalignant lesions as targets for cancer vaccines.
Finn
Olivera J
OJ
University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA 15261, USA. ojfinn@pitt.edu
D019496:Cancer Vaccines / Q000627:therapeutic use*; D019926:Cyclin B / Q000276:immunology; D056744:Cyclin B1; D006801:Humans; D007111:Immunity, Cellular; D018396:Mucin-1 / Q000276:immunology; D011230:Precancerous Conditions / Q000276:immunology / Q000628:therapy*
C534699:CCNB1 protein, human; D019496:Cancer Vaccines; D019926:Cyclin B; D056744:Cyclin B1; D018396:Mucin-1